Facebook 
Masuk dengan Email
- Pendahuluan
- Farmakologi
- Formulasi
- Indikasi dan Dosis
- Efek Samping dan Interaksi Obat
- Penggunaan pada Kehamilan dan Ibu Menyusui
- Kontraindikasi dan Peringatan
- Pengawasan Klinis
Farmakologi Methylprednisolone
Farmakologi methylprednisolone adalah sebagai glukokortikoid dengan efek antiinflamasi dan imunosupresi. Methylprednisolone bekerja dengan menghambat sintesis beberapa protein inflamasi melalui penekanan gen yang mengkode protein tersebut.[1-3]
Farmakodinamik
Referensi
1. Mehta J, Rolta R, Mehta BB, Kaushik N, Choi EH, Kaushik NK. Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review. Vol. 13, Frontiers in Microbiology. Frontiers Media S.A.; 2022.
2. MIMS. Methylprednisolone. 2022. https://www.mims.com/indonesia/drug/info/methylprednisolone?mtype=generic
3. Drugbank. Methylprednisolone. 2022. https://go.drugbank.com/drugs/DB00959
4. Xiang Z, Liu J, Shi D, Chen W, Li J, Yan R, et al. Glucocorticoids improve severe or critical covid-19 by activating ace2 and reducing il-6 levels. International Journal of Biological Sciences. 2020;16(13):2382–91.
5. Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V, Shahriarirad R, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infectious Diseases. 2021 Dec 1;21(1).
6. Annane D, Pastores SM, Arlt W, Balk RA, Beishuizen A, Briegel J, et al. Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Vol. 43, Intensive Care Medicine. Springer Verlag; 2017. p. 1781–92.
7. Qi X, Li X, Zhao Y, Wu X, Chen F, Ma X, et al. Treating steroid refractory intestinal acute graft-vs.-Host disease with fecal microbiota transplantation: A pilot study. Frontiers in Immunology. 2018 Sep 25;9(SEP).
8. Danylesko I, Bukauskas A, Paulson M, Peceliunas V, Gedde-Dahl d.y T, Shimoni A, et al. Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease. Bone Marrow Transplantation. 2019 Jul 1;54(7):987–93.
9. Fløisand Y, Schroeder MA, Chevallier P, Selleslag D, Devine S, Renteria AS, et al. A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease. Bone Marrow Transplantation. 2021 Oct 1;56(10):2477–88.
10. Bacigalupo A, Angelucci E, Raiola AM, Varaldo R, di Grazia C, Gualandi F, et al. Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody—Begelomab. Bone Marrow Transplantation. 2020 Aug 1;55(8):1580–7.
11. Dogan N, Hüsing-Kabar A, Schmidt HH, Cicinnati VR, Beckebaum S, Kabar I. Acute allograft rejection in liver transplant recipients: Incidence, risk factors, treatment success, and impact on graft failure. Journal of International Medical Research. 2018 Sep 1;46(9):3979–90.
(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)
